JP2015520169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520169A5 JP2015520169A5 JP2015514099A JP2015514099A JP2015520169A5 JP 2015520169 A5 JP2015520169 A5 JP 2015520169A5 JP 2015514099 A JP2015514099 A JP 2015514099A JP 2015514099 A JP2015514099 A JP 2015514099A JP 2015520169 A5 JP2015520169 A5 JP 2015520169A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding entity
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102000013691 Interleukin-17 Human genes 0.000 claims 9
- 108050003558 Interleukin-17 Proteins 0.000 claims 9
- 102000013264 Interleukin-23 Human genes 0.000 claims 7
- 108010065637 Interleukin-23 Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims 3
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims 3
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims 3
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 3
- 206010053869 POEMS syndrome Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019375 Helicobacter infections Diseases 0.000 claims 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 206010023335 Keratitis interstitial Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000024526 cutaneous mucinosis Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000006904 interstitial keratitis Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000010241 mucinoses Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650286P | 2012-05-22 | 2012-05-22 | |
| US61/650,286 | 2012-05-22 | ||
| US201361784600P | 2013-03-14 | 2013-03-14 | |
| US61/784,600 | 2013-03-14 | ||
| US201361787890P | 2013-03-15 | 2013-03-15 | |
| US61/787,890 | 2013-03-15 | ||
| PCT/US2013/041928 WO2013177101A2 (en) | 2012-05-22 | 2013-05-21 | Bispecific antibodies and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520169A JP2015520169A (ja) | 2015-07-16 |
| JP2015520169A5 true JP2015520169A5 (enExample) | 2016-07-14 |
| JP6362587B2 JP6362587B2 (ja) | 2018-07-25 |
Family
ID=48539425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514099A Expired - Fee Related JP6362587B2 (ja) | 2012-05-22 | 2013-05-21 | Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US8945553B2 (enExample) |
| EP (2) | EP2852615B1 (enExample) |
| JP (1) | JP6362587B2 (enExample) |
| CN (1) | CN104884473B (enExample) |
| AR (1) | AR091116A1 (enExample) |
| ES (2) | ES2846623T3 (enExample) |
| LT (1) | LT2852615T (enExample) |
| SI (1) | SI2852615T1 (enExample) |
| TW (1) | TWI609882B (enExample) |
| UY (1) | UY34815A (enExample) |
| WO (1) | WO2013177101A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| WO2007106769A2 (en) | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| TWI681972B (zh) | 2014-03-19 | 2020-01-11 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途 |
| EP3126384B1 (en) | 2014-04-01 | 2020-12-02 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| JP6974943B2 (ja) * | 2014-05-13 | 2021-12-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用 |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| CN106796221B (zh) * | 2014-07-24 | 2019-12-17 | 陈垣崇 | 川崎氏症的诊断与治疗 |
| SG11201705323WA (en) * | 2015-01-16 | 2017-07-28 | Academia Sinica | Molecular constructs with targeting and effector elements |
| CN107407677B (zh) * | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
| MX2017015260A (es) | 2015-06-03 | 2018-02-19 | Squibb Bristol Myers Co | Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer. |
| CN107949570A (zh) * | 2015-06-30 | 2018-04-20 | 勃林格殷格翰国际有限公司 | 多特异性结合蛋白 |
| PE20180774A1 (es) * | 2015-07-23 | 2018-05-07 | Boehringer Ingelheim Int | Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos |
| EP3347035A4 (en) | 2015-09-09 | 2019-05-01 | Fred Hutchinson Cancer Research Center | CARTON PEPTIDES |
| ES2926969T3 (es) | 2015-11-19 | 2022-10-31 | Bristol Myers Squibb Co | Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11028410B2 (en) | 2016-01-27 | 2021-06-08 | Just-Evotec Biologics, Inc. | Hybrid promoter and uses thereof |
| WO2018050028A1 (zh) | 2016-09-14 | 2018-03-22 | 北京韩美药品有限公司 | 一种能够特异性地结合il-17a的抗体及其功能片段 |
| KR102321861B1 (ko) * | 2017-03-10 | 2021-11-05 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도 |
| JP7280193B2 (ja) * | 2017-03-16 | 2023-05-23 | ブレイズ バイオサイエンス， インコーポレイテッド | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
| US11685787B2 (en) | 2017-05-16 | 2023-06-27 | Bristol-Myers Squibb Company | Treatment of cancer with anti-GITR agonist antibodies |
| CN107384960B (zh) * | 2017-07-25 | 2020-06-12 | 吉优诺（上海）基因科技有限公司 | 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用 |
| CN107854490A (zh) * | 2017-09-26 | 2018-03-30 | 首都医科大学附属北京世纪坛医院 | 一种经修饰的t细胞及其应用 |
| RU2020117362A (ru) | 2017-11-02 | 2021-12-02 | Новартис Аг | Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17) |
| KR102048475B1 (ko) * | 2017-11-10 | 2019-11-26 | 주식회사 와이바이오로직스 | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN108929903B (zh) * | 2018-04-23 | 2021-07-16 | 东莞市第五人民医院(东莞市太平人民医院) | 用于慢性牙周炎筛查、诊断、疗效评价的标志物及试剂盒 |
| AU2019386021B2 (en) * | 2018-11-27 | 2024-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-il-23p19 antibody and uses thereof |
| EP3954707A1 (en) * | 2018-12-21 | 2022-02-16 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Protease cleavable bispecific antibodies and uses thereof |
| CN110330566A (zh) * | 2019-06-11 | 2019-10-15 | 南京华岩生物技术有限公司 | 一种具有双重可变结构域的双特异性结合的免疫球蛋白 |
| BR112022021789A2 (pt) | 2020-04-27 | 2023-03-07 | Twist Bioscience Corp | Bibliotecas de ácido nucléico variantes para coronavírus |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021238932A1 (zh) * | 2020-05-26 | 2021-12-02 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| CN112807428B (zh) * | 2020-06-12 | 2024-08-27 | 江苏荃信生物医药股份有限公司 | 包含抗人白介素23单克隆抗体的药物组合物 |
| CN111944046B (zh) * | 2020-08-28 | 2021-04-09 | 江苏荃信生物医药有限公司 | 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法 |
| CA3253618A1 (en) | 2022-05-16 | 2023-11-23 | Novartis Ag | METHODS FOR TREATMENT OF GIANT CELL ARTERITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS |
| EP4525914A1 (en) | 2022-05-18 | 2025-03-26 | Novartis AG | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |
| WO2025245150A1 (en) * | 2024-05-20 | 2025-11-27 | The Trustees Of Columbia University In The City Of New York | Anti-pd-1 x il-25 bispecific antibody to treat cancer |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US6291189B1 (en) | 1994-05-10 | 2001-09-18 | Carta Proteomics, Inc. | Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites |
| US5658739A (en) | 1994-05-10 | 1997-08-19 | The Regents Of The University Of California | Method for characterization of the fine structure of protein binding sites |
| US6902735B1 (en) | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| ATE474849T1 (de) | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
| CN101333256A (zh) | 1999-03-25 | 2008-12-31 | 艾博特股份有限两合公司 | 结合人il-12的人抗体及其生产方法 |
| US20030199041A1 (en) | 1999-07-07 | 2003-10-23 | Presnell Scott R. | Interleukin-17 receptor homologue |
| SI2857516T1 (sl) * | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| EP2784084B2 (en) | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
| DK1648509T3 (da) | 2003-07-15 | 2013-01-07 | Amgen Inc | Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer |
| WO2005056772A1 (en) | 2003-12-09 | 2005-06-23 | Novozymes Inc. | Methods for eliminating or reducing the expression of genes in filamentous fungal strains |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| US7501247B2 (en) | 2004-05-03 | 2009-03-10 | Schering Corporation | Method of treating skin inflammation |
| CN101001871A (zh) | 2004-06-10 | 2007-07-18 | 津莫吉尼蒂克斯公司 | 可溶性ZcytoR14、抗ZcytoR14抗体和结合伴侣以及在炎症中的使用方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2596509A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| EP3501537A1 (en) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007024846A2 (en) | 2005-08-25 | 2007-03-01 | Eli Lilly And Company | Anit-il-23 antibiodies |
| SG165322A1 (en) | 2005-08-31 | 2010-10-28 | Schering Corp | Engineered anti-il-23 antibodies |
| WO2007027761A2 (en) | 2005-09-01 | 2007-03-08 | Schering Corporation | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
| CN101326195B9 (zh) * | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| AU2007235199B8 (en) | 2006-01-31 | 2010-10-28 | Novartis Ag | IL-17 antagonistic antibodies for treating cancer |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| WO2007106769A2 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
| TWI390034B (zh) | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
| AU2007260787A1 (en) * | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| BRPI0715917A2 (pt) | 2006-08-11 | 2014-11-25 | Schering Corp | Anticorpos para il-17a |
| CA2682889C (en) * | 2007-04-27 | 2016-04-05 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
| EP2392597B1 (en) * | 2007-04-27 | 2014-04-02 | ZymoGenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| CA2700714C (en) * | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| WO2009131239A1 (ja) | 2008-04-25 | 2009-10-29 | Kyowa Hakko Kirin Co Ltd | 安定な多価抗体 |
| SG190626A1 (en) | 2008-05-05 | 2013-06-28 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2810652A3 (en) | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
| WO2012009760A1 (en) * | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
-
2013
- 2013-05-21 SI SI201331310T patent/SI2852615T1/sl unknown
- 2013-05-21 US US13/898,544 patent/US8945553B2/en active Active
- 2013-05-21 WO PCT/US2013/041928 patent/WO2013177101A2/en not_active Ceased
- 2013-05-21 CN CN201380038828.XA patent/CN104884473B/zh not_active Expired - Fee Related
- 2013-05-21 EP EP13726375.2A patent/EP2852615B1/en active Active
- 2013-05-21 LT LTEP13726375.2T patent/LT2852615T/lt unknown
- 2013-05-21 ES ES18202356T patent/ES2846623T3/es active Active
- 2013-05-21 AR ARP130101765 patent/AR091116A1/es unknown
- 2013-05-21 ES ES13726375T patent/ES2711554T3/es active Active
- 2013-05-21 US US14/402,322 patent/US9708401B2/en active Active
- 2013-05-21 JP JP2015514099A patent/JP6362587B2/ja not_active Expired - Fee Related
- 2013-05-21 TW TW102117991A patent/TWI609882B/zh not_active IP Right Cessation
- 2013-05-21 UY UY0001034815A patent/UY34815A/es unknown
- 2013-05-21 EP EP18202356.4A patent/EP3456741B1/en not_active Not-in-force
-
2014
- 2014-12-19 US US14/576,278 patent/US9783606B2/en active Active
-
2016
- 2016-10-10 US US15/289,463 patent/US20170022272A1/en not_active Abandoned
-
2017
- 2017-06-12 US US15/620,358 patent/US10358489B2/en active Active
- 2017-09-01 US US15/694,374 patent/US10358490B2/en active Active
-
2019
- 2019-06-10 US US16/435,960 patent/US11254740B2/en active Active
-
2022
- 2022-01-07 US US17/570,954 patent/US20220185877A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520169A5 (enExample) | ||
| AU2020202770B2 (en) | Novel antibody frameworks | |
| IL314885A (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| IL277678A (en) | Anti-trem-1 antibodies and uses thereof | |
| JP2018516853A5 (enExample) | ||
| CN107001458B (zh) | 基于可变结构域vl和vhh衍生物的高亲和力和聚集稳定的抗体 | |
| JP2010538608A5 (enExample) | ||
| JP2011526493A5 (enExample) | ||
| JP2020519308A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2012501669A5 (enExample) | ||
| RU2013109397A (ru) | Антитела, направленные против il-17 | |
| JP2017523984A5 (enExample) | ||
| FI3841120T3 (fi) | Sitrullinoituun histoni 2A:han ja/tai 4:ään sitoutuvia vasta-aineita | |
| JP2013537414A5 (enExample) | ||
| TWI869542B (zh) | 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途 | |
| JP2022060392A (ja) | 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法 | |
| JPWO2019195126A5 (enExample) | ||
| JPWO2022111425A5 (enExample) | ||
| JP2019533423A (ja) | ＢＬｙＳ抗体及びその製造方法と応用 | |
| JPWO2021133723A5 (enExample) | ||
| JPWO2022226342A5 (enExample) | ||
| JP2020533953A5 (enExample) | ||
| JP2020505465A5 (enExample) |